Alter H.Block T.Brown N.Brownstein A.Brosgart C.Chang K.-M.PEI-JER CHENChisari F.V.Cohen C.El-Serag H.Feld J.Gish R.Glenn J.Greten T.Guo H.Guo J.-T.Hoshida Y.Hu J.Kowdley K.V.Li W.Liang J.Locarnini S.Lok A.S.Mason W.McMahon B.Mehta A.Perrillo R.Revill P.Rice C.M.Rinaudo J.Schinazi R.Seeger C.Shetty K.Tavis J.Zoulim F.2021-07-032021-07-0320180270-9139https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040970152&doi=10.1002%2fhep.29509&partnerID=40&md5=a07f2a43c8b03e542a7df5de81c5b239https://scholars.lib.ntu.edu.tw/handle/123456789/568345[SDGs]SDG3antivirus agent; neutralizing antibody; antivirus agent; virus DNA; antiviral therapy; Article; chronic hepatitis B; cytotoxic T lymphocyte; DNA virus; Hepatitis B virus; human; liver cell carcinoma; morbidity; mortality; nonhuman; priority journal; T lymphocyte; T lymphocyte activation; virogenesis; virus genome; chronic hepatitis B; drug development; drug effect; genetics; medical research; procedures; virology; Antiviral Agents; Biomedical Research; DNA, Viral; Drug Discovery; Hepatitis B virus; Hepatitis B, Chronic; Humansjournal article10.1002/hep.29509288775492-s2.0-85040970152